Replies to post #301975 on Bioelectronics Corp (BIEL)

[pinhigh]

Great point Srin....it's hard to sell a lot of product to only 206,000 potential users. With today's 13,000,000 million potential users of Biel's tech the game has completely changed.

[JNdouble1]

Did I forget to include the possibilities of off label prescription?

My bad. You see, doctors can prescribe the device for other things than what it was initially cleared for. If they really believed in it, they would use it for other surgeries that are performed in their clinic. They would tell their surgeon friends who tell their surgeon friends...

Maybe I also forgot to include the point about how easy it should have been to gain new prescription indications for the device other than eye surgery. With all the eye surgeons using it and believing in it's potential, clinical trials and approvals should have been a snap.

Well, of course a decade and a half later and here we are. We have the expanded indications now. What gives a new investor pause, is that the product didn't gain any traction among surgeons (not even the limited pool of eye surgeons). We know all too well, that the OTC version of the product has never lived up to its expectations.

Throwing numbers around is a good distraction, my point was that the surgical community for which ActiBand was cleared didn't adopt the product. This fact, as I say, gives me pause when putting my money on the success of RecoveryRx